EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID ‐19 outcome: Results of a pilot observational study

J E Niño-Ramírez iD, M Alcoceba iD, M N Gutiérrez-Zufiaurre iD, M Marcos iD, F J Gil-Etayo iD, M R Bartol-Sánchez iD, R Eiros iD, M C Chillón iD, M García-Álvarez iD, P Terradillos-Sánchez iD, D Presa, J L Muñoz und 8 weitere

HLA · 2024

DOI: 10.1111/tan.15640 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift HLA, 2024. Verfasst von J E Niño-Ramírez und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanc…. Hauptthemen laut MEDLINE: COVID-19, Receptors, KIR, SARS-CoV-2. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Gerencia Regional de Salud de Castilla y Leon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pathogenesis of COVID‐19 warrants unravelling. Genetic polymorphism analysis may help answer the variability in disease outcome. To determine the role of KIR and HLA polymorphisms in susceptibility, progression, and severity of SARS‐CoV‐2 infection, 458 patients and 667 controls enrolled in this retrospective observational study from April to December 2020. Mild/moderate and severe/death study groups were established. HLA‐A , ‐B , ‐C , and KIR genotyping were performed using the Lifecodes® HLA‐SSO and KIR‐SSO kits on the Luminex® 200™ xMAP fluoroanalyser. A probability score using multivariate binary logistic regression analysis was calculated to estimate the likelihood of severe COVID‐19. ROC analysis was used to calculate the best cut‐off point for predicting a worse clinical outcome with high sensitivity and specificity. A p ≤ 0.05 was considered statistically significant. KIR AA genotype protected positively against severity/death from COVID‐19. Furthermore, KIR3DL1 , KIR2DL3 and KIR2DS4 genes protected patients from severe forms of COVID‐19. KIR Bx genotype, as well as KIR2DL2 , KIR2DS2 , KIR2DS3 and KIR3DS1 were identified as biomarkers of severe COVID‐19. Our logistic regression model, which included clinical and KIR/HLA variables, categorised our cohort of patients as high/low risk for severe COVID‐19 disease with high sensitivity and specificity (Se = 94.29%, 95% CI [80.84–99.30]; Sp = 84.55%, 95% CI [79.26–88.94]; OR = 47.58, 95%CI [11.73–193.12], p < 0.0001). These results illustrate an association between KIR/HLA ligand polymorphism and different COVID‐19 outcomes and remarks the possibility of use them as a surrogate biomarkers to detect severe patients in possible future infectious outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Receptors, KIRSARS-CoV-2HumansMaleFemaleMiddle AgedPilot ProjectsRetrospective StudiesPolymorphism, GeneticAgedGenotypeGenetic Predisposition to DiseaseAdultSeverity of Illness IndexHLA Antigens

Stichwörter der Autor:innen

COVID‐19HLAKIRimmunogeneticspolymorphism

Substanzen

Receptors, KIRHLA Antigens

Autor:innen und Institutionen

  • Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERONC, Centro de Investigación del Cáncer (CIC) and Univ…
  • Servicio de Microbiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain.
  • Servicio de Medicina Interna, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain.
  • Servicio de Neumología, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Servicio de Cardiología, Hospital Universitario de Salamanca, IBSAL, USAL, CIBERCV, Salamanca, Spain.
  • Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, Spain.

ORCID-Profile: J E Niño-Ramírez, M Alcoceba, M N Gutiérrez-Zufiaurre, M Marcos, F J Gil-Etayo, M R Bartol-Sánchez, R Eiros, M C Chillón, M García-Álvarez, P Terradillos-Sánchez, A López-Bernús, D González-Calle, O Compán-Fernández, M González, R García-Sanz, F Boix

Förderung

  • Gerencia Regional de Salud de Castilla y Leon

Zitieren

APA

Niño-Ramírez, J. E., Alcoceba, M., Gutiérrez-Zufiaurre, M. N., Marcos, M., Gil-Etayo, F. J., Bartol-Sánchez, M. R., Eiros, R., Chillón, M. C., García-Álvarez, M., Terradillos-Sánchez, P., Presa, D., Muñoz, J. L., López-Bernús, A., López-Sánchez, E., González-Calle, D., Sánchez, P. L., Compán-Fernández, O., González, M., García-Sanz, R., & Boix, F. (2024). Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID ‐19 outcome: Results of a pilot observational study. HLA. https://doi.org/10.1111/tan.15640

Vancouver

Niño-Ramírez JE, Alcoceba M, Gutiérrez-Zufiaurre MN, Marcos M, Gil-Etayo FJ, Bartol-Sánchez MR, et al. Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID ‐19 outcome: Results of a pilot observational study. HLA. 2024. doi:10.1111/tan.15640

BibTeX
@article{NioRamrez2024,
  author = {Niño-Ramírez, J E and Alcoceba, M and Gutiérrez-Zufiaurre, M N and Marcos, M and Gil-Etayo, F J and Bartol-Sánchez, M R and Eiros, R and Chillón, M C and García-Álvarez, M and Terradillos-Sánchez, P and Presa, D and Muñoz, J L and López-Bernús, A and López-Sánchez, E and González-Calle, D and Sánchez, P L and Compán-Fernández, O and González, M and García-Sanz, R and Boix, F},
  title = {Killer‐cell immunoglobulin‐like receptor polymorphism is associated with COVID ‐19 outcome: Results of a pilot observational study},
  journal = {HLA},
  year = {2024},
  doi = {10.1111/tan.15640}
}
Kostenlos starten →